IDEXX Laboratories (IDEXX Laboratories) LT-Debt-to-Total-Asset

: 0.22 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. IDEXX Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.22.

IDEXX Laboratories's long-term debt to total assets ratio declined from Dec. 2022 (0.29) to Dec. 2023 (0.22). It may suggest that IDEXX Laboratories is progressively becoming less dependent on debt to grow their business.

IDEXX Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for IDEXX Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.42

0.41

0.35

0.29

0.22

IDEXX Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset																0.29	0.28	0.28	0.23	0.22

IDEXX Laboratories LT-Debt-to-Total-Asset Calculation

IDEXX Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	722.554	/	3259.925
	=	0.22

IDEXX Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	722.554	/	3259.925
	=	0.22

IDEXX Laboratories (NAS:IDXX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

IDEXX Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories (IDEXX Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

IDXX:Mexico IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.

Executives

James F Polewaczyk	officer: Corporate Vice President	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky	director, officer: President and CEO	ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers	director, officer: President & CEO	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt	director	CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin	director	7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley	director	C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak	director	C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg	officer: EVP, GC & Corporate Secretary	EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek	director	6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451